H.R. 242
Referred to CommitteeMedicare Prescription Drug Price Negotiation Act of 2017
Latest Action
Referred to the Subcommittee on Health.
1/25/2017 • House
Summary
Medicare Prescription Drug Price Negotiation Act of 2017
This bill amends title XVIII (Medicare) of the Social Security Act to require the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. Current law prohibits CMS from doing so.
Introduced in House • 1/4/2017
Topics & Subjects
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (46)
Party Breakdown
Sponsor
Cosponsors (45)
Bill Journey
Originated in the House
Introduced
January 4, 2017
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (1)
Related Bills (5)
H.R. 3748
Medicare Buy-In and Health Care Stabilization Act of 2017
S. 1688
Empowering Medicare Seniors to Negotiate Drug Prices Act of 2017
H.R. 275
Medicare Prescription Drug Price Negotiation Act of 2019
S. 41
Medicare Prescription Drug Price Negotiation Act of 2017
H.R. 3061
Medicare Prescription Drug Price Negotiation Act of 2015